Clinical significance of serum soluble semaphorin 4D for predicting diabetic microangiopathy in type 2 diabetic patients

Abstract

Objective To detect the levels of serum soluble semaphorin 4D in patients with type 2 diabetes, and to investigate the predictable value for diabetic microangiopathy (DMAP). Methods A total of 210 type 2 diabetes patients were divided into non-DMAP group (96 cases), single-DMAP group (77 cases) and composite DMAP group (combination of two or three DMAP, 37 cases) according to the DMAP status. The general clinical data and laboratory indicators were collected, meanwhile, the levels of serum soluble semaphorin 4D were measured by enzyme-linked immunosorbent assay. The risk factors related to DMAP were analyzed by multiple ordered Logistic regression model, and the predictable value of serum soluble semaphorin 4D for DMAP was evaluated by receiver operating characteristic (ROC) curve. Results The difference of course of diabetes [(5.02 ±1.00), (6.26 ± 2.13), (8.42 ± 2.82) years], systolic blood pressure (SBP)[(131.81 ± 18.06), (141.81 ± 22.51), (142.88 ± 17.06) mmHg, 1 mmHg=0.133 kPa], hypertension ratio [37.5%(36/96), 50.6%(39/77), 35.1%(22/37)], postprandial blood glucose (PPG)[(13.56 ± 2.02), (14.94 ± 2.50), (15.88 ± 2.45) mmol/L], hemoglobin (HbA1c) [(8.17 ± 2.17)%, (9.14 ± 1.51)%, (9.69 ±1.58)%], soluble semaphorin 4D [(1.18 ± 0.27), (1.89 ± 0.53), (2.21 ± 0.79) μg/L] among non-DMAP group, single-DMAP group, composite DMAP group had statistical significance (P 1.52 μg/L (AUC=0.873) may indicate the occurrence of single DMAP, whereas serum soluble semaphorin 4D>1.91μg/L (AUC=0.740) may predictethe occurrence of composite DMAP. Conclusions Serum soluble semaphorin 4D is an independent risk factors for DMAP and may be considered as an potential serum maker to screen DMAP. Key words: Diabetes mellitus, type 2; Serum soluble semaphorin 4D; Diabetic microangiopathy; Prediction